Brokerages Expect Editas Medicine, Inc. (NASDAQ:EDIT) to Announce -$0.84 EPS

Brokerages expect Editas Medicine, Inc. (NASDAQ:EDITGet Rating) to announce ($0.84) earnings per share (EPS) for the current fiscal quarter, according to Zacks Investment Research. Five analysts have issued estimates for Editas Medicine’s earnings, with estimates ranging from ($0.93) to ($0.72). Editas Medicine reported earnings of ($0.81) per share in the same quarter last year, which suggests a negative year-over-year growth rate of 3.7%. The business is expected to report its next earnings report on Monday, January 1st.

According to Zacks, analysts expect that Editas Medicine will report full-year earnings of ($3.41) per share for the current financial year, with EPS estimates ranging from ($3.83) to ($2.85). For the next fiscal year, analysts forecast that the firm will post earnings of ($3.38) per share, with EPS estimates ranging from ($3.85) to ($2.90). Zacks’ earnings per share averages are an average based on a survey of research firms that that provide coverage for Editas Medicine.

Editas Medicine (NASDAQ:EDITGet Rating) last posted its quarterly earnings results on Wednesday, May 4th. The company reported ($0.74) EPS for the quarter, topping the consensus estimate of ($0.81) by $0.07. The firm had revenue of $6.80 million for the quarter, compared to the consensus estimate of $3.85 million. Editas Medicine had a negative net margin of 721.60% and a negative return on equity of 32.88%. The business’s revenue was up 4.6% compared to the same quarter last year. During the same period last year, the firm posted ($0.86) earnings per share.

A number of brokerages recently issued reports on EDIT. Oppenheimer dropped their price target on shares of Editas Medicine from $55.00 to $28.00 in a research note on Thursday, May 5th. SVB Leerink reduced their price target on shares of Editas Medicine from $41.00 to $27.00 and set a “market perform” rating for the company in a research report on Friday, February 25th. Morgan Stanley upped their price target on shares of Editas Medicine from $16.00 to $17.00 and gave the company an “underweight” rating in a research report on Tuesday, April 12th. Evercore ISI lowered shares of Editas Medicine to a “hold” rating and set a $15.00 price target for the company. in a research report on Friday, February 11th. Finally, StockNews.com started coverage on shares of Editas Medicine in a research report on Thursday, March 31st. They set a “sell” rating for the company. Three equities research analysts have rated the stock with a sell rating, three have assigned a hold rating and five have given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $32.00.

NASDAQ:EDIT traded up $0.37 during trading hours on Friday, hitting $11.91. The company had a trading volume of 1,140,117 shares, compared to its average volume of 1,575,571. The company has a market capitalization of $817.50 million, a PE ratio of -4.36 and a beta of 2.07. The stock has a 50-day moving average price of $14.48 and a 200 day moving average price of $19.66. Editas Medicine has a 52 week low of $9.71 and a 52 week high of $73.03.

Hedge funds have recently bought and sold shares of the business. First Republic Investment Management Inc. bought a new position in shares of Editas Medicine during the 3rd quarter valued at approximately $206,000. Rockefeller Capital Management L.P. boosted its position in shares of Editas Medicine by 214.0% during the 3rd quarter. Rockefeller Capital Management L.P. now owns 7,893 shares of the company’s stock valued at $323,000 after acquiring an additional 5,379 shares during the last quarter. GSA Capital Partners LLP bought a new position in shares of Editas Medicine during the 3rd quarter valued at approximately $282,000. Franklin Resources Inc. boosted its position in shares of Editas Medicine by 92.1% during the 3rd quarter. Franklin Resources Inc. now owns 8,849 shares of the company’s stock valued at $363,000 after acquiring an additional 4,243 shares during the last quarter. Finally, Dimensional Fund Advisors LP boosted its position in shares of Editas Medicine by 12.8% during the 3rd quarter. Dimensional Fund Advisors LP now owns 709,766 shares of the company’s stock valued at $29,160,000 after acquiring an additional 80,735 shares during the last quarter. Institutional investors and hedge funds own 75.48% of the company’s stock.

About Editas Medicine (Get Rating)

Editas Medicine, Inc, a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads to inherited childhood blindness.

Read More

Get a free copy of the Zacks research report on Editas Medicine (EDIT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Editas Medicine (NASDAQ:EDIT)

Want More Great Investing Ideas?

Receive News & Ratings for Editas Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Editas Medicine and related companies with MarketBeat.com's FREE daily email newsletter.